SCHEMBL171877

SCHEMBL171877

Cc1ccc(CC(=O)N(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTBP2 P56545 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
HPGD P15428 4/20 0.46
TDP1 Q9NUW8 2/20 0.46
POLB P06746 1/20 0.46
APEX1 P27695 1/20 0.46
LTB4R Q15722 1/20 0.46
LTB4R2 Q9NPC1 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
CNR2 P34972 2/20 0.45
KDM4E B2RXH2 1/20 0.44
LMNA P02545 1/20 0.44
ALB P02768 1/20 0.44
CYP3A4 P08684 1/20 0.44
CHRM1 P11229 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRB1 P18505 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Toluene SCHEMBL5404912 0.92 TDP1 (0.53) CTBP2L3MBTL1TDP1LTB4RLTB4R2
SCHEMBL4432977 0.83 CTBP2 (0.46) CTBP2L3MBTL1NPC1RAB9AHPGD
SCHEMBL10567198 0.83 CA2 (0.56) HPGDTDP1POLBAPEX1LTB4R
SCHEMBL14340565 0.83 ALDH1A1 (0.48) HPGDTDP1POLBAPEX1KMT2A
SCHEMBL15920608 0.83 HDAC4 (0.44) TDP1POLBAPEX1HDAC4HDAC6
SCHEMBL1973647 0.83 CA2 (0.56) CTBP2NPC1RAB9ALMNAHDAC4
SCHEMBL24835513 0.82 LTB4R (0.49) CTBP2L3MBTL1NPC1RAB9AHPGD
SCHEMBL8143899 0.81 CYP2D6 (0.46) TDP1POLBAPEX1KDM4EOPRK1
SCHEMBL14959151 0.81 TDP1 (0.62) CTBP2TDP1POLBAPEX1KMT2A
SCHEMBL15920640 0.81 CA1 (0.45) RAB9ATDP1POLBAPEX1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203915-A1 Process for the preparation of solifenacin DIPHARMA FRANCIS S.R.L. (IT) 2009-08-13 US claimed
EP-2088148-A2 \"Process for the preparation of solifenacin\ Dipharma Francis S.r.l. (IT) 2009-08-12 EP claimed
US-11940729-B2 Photosensitive composition, negative photosensitive composition, pixel division layer and organic EL display device TORAY INDUSTRIES, INC. (JP) 2024-03-26 US disclosed
US-20230127537-A1 PHOTOSENSITIVE COMPOSITION, NEGATIVE PHOTOSENSITIVE COMPOSITION, PIXEL DIVISION LAYER AND ORGANIC EL DISPLAY DEVICE TORAY INDUSTRIES, INC. (JP) 2023-04-27 US disclosed
US-20220177443-A1 SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-06-09 US disclosed
WO-2022095989-A1 P300 INHIBITORS AND USE THEREOF IN MEDICINE 贝达药业股份有限公司 2022-05-12 WO disclosed
WO-2020117759-A1 SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-06-11 WO disclosed
WO-2019136022-A1 PERIODONTAL DISEASE THERAPY NEW YORK UNIVERSITY (US) 2019-07-11 WO disclosed
US-20180085327-A1 Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity ACADIA PHARMACEUTICALS INC. 2018-03-29 US disclosed
US-9481670-B2 Triazine compounds SPHAERA PHARMA PTE. LTD. (SG) 2016-11-01 US disclosed
US-9266834-B2 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors Janssen Pharmaceuticals, Inc. (US) 2016-02-23 US disclosed
US-4655843-A Silane diimidic tetracarboxylic perylene dyes and composite pigments MONTEDISON S.P.A. (IT) 1987-04-07 US disclosed
EP-0204842-A1 NODULAR COPOLYMERS FORMED OF ALPHA-OLEFIN COPOLYMERS COUPLED BY NON-CONJUGATED DIENES. EXXON RESEARCH ENGINEERING CO (US) 1986-12-17 EP disclosed
EP-0204840-A1 MOLECULAR WEIGHT DISTRIBUTION MODIFICATION IN TUBULAR REACTOR EXXON RESEARCH AND ENGINEERING COMPANY (US) 1986-12-17 EP disclosed
US-4613667-A PAINTS, ENAMELS, PLASTICS, INSK MONTEDISON S.P.A. (IT) 1986-09-23 US disclosed
WO-1986003756-A1 MOLECULAR WEIGHT DISTRIBUTION MODIFICATION IN TUBULAR REACTOR EXXON RESEARCH AND ENGINEERING COMPANY (US) 1986-07-03 WO disclosed
WO-1986003755-A1 NODULAR COPOLYMERS FORMED OF ALPHA-OLEFIN COPOLYMERS COUPLED BY NON-CONJUGATED DIENES EXXON RESEARCH AND ENGINEERING COMPANY (US) 1986-07-03 WO disclosed
US-4540753-A COORDINATION CATALYST EXXON RESEARCH & ENGINEERING CO. (US) 1985-09-10 US disclosed
EP-0140688-A2 Silane perylene dyes, composite pigments obtainable therefrom, and processes for preparing the same Montedison S.p.A. (IT) 1985-05-08 EP disclosed
EP-0129414-A2 Narrow MWD alpha-olefin copolymers EXXON RESEARCH AND ENGINEERING COMPANY (US) 1984-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220177443-A1 SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE IKZF2, IKZF1, IKZF3 CTBP2 406/4885L3MBTL1 2499/4885NPC1 2462/4885
US-20090203915-A1 Process for the preparation of solifenacin OPRL1, CHRNE, OPRK1 CTBP2 3403/4885L3MBTL1 4765/4885NPC1 3633/4885
US-20180085327-A1 Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity SLC6A4, HTR4, GPR34 CTBP2 3450/4885L3MBTL1 1939/4885NPC1 962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.